ArticleCancer diagnosis & prognosis
Clinical Significance of HER2-low Expression in Triple-negative Breast Cancer: A Retrospective Multicenter Study.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging role of human epidermal growth factor 2-low status in the prognosis and management of triple-negative breast cancer: a narrative review.Translational cancer research · 2026Review
- A multigene model for response stratification to neoadjuvant chemotherapy in triple negative breast cancer.Breast (Edinburgh, Scotland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: The clinical significance of human epidermal growth factor receptor 2 (HER2)-low expression in triple-negative breast cancer (TNBC) remains unclear. Although the emergence of antibody-drug conjugates has drawn attention to HER2-low tumors, whether HER2-low represents a biologically distinct subtype within TNBC is still under investigation. Patients and Methods: We retrospectively analyzed 261 patients with TNBC who underwent neoadjuvant chemotherapy followed by curative surgery at four institutions between 2008 and 2018. Clinicopathological features, chemotherapy effect, and patient outcomes were compared between HER2-low and HER2-null groups. Results: No significant differences were observed in pathological complete response rates or survival outcomes between the HER2-low and HER2-null groups. However, compared to HER2-low tumors, HER2-null tumors showed a significantly higher Ki67 labeling index ( Conclusion: Although the HER2-low and HER2-null tumor groups among TNBC showed no significant differences in response to neoadjuvant chemotherapy or patient outcomes, the higher proliferative activity and differing outcome trends in HER2-null tumors suggest possible biological differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.